(Q37563976)

21 August 2017

1 reference

title

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules (English)

1 reference

21 August 2017

1 reference

2

Evanthia Galanis

1 reference

21 August 2017

Axel Grothey

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

28 July 2009

1 reference

Nature Reviews Clinical Oncology

21 August 2017

published in

1 reference

21 August 2017

volume

6

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

507-518

1 reference

Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Angiogenesis: an organizing principle for drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Cellular abnormalities of blood vessels as targets in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Angiogenesis in brain tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

The biology of VEGF and its receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Angiogenesis in cancer and other diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Angiogenesis in life, disease and medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Positive and negative modulation of angiogenesis by VEGFR1 ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

The role of angiopoietins during angiogenesis in gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Vascular-specific growth factors and blood vessel formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

The PDGF family: four gene products form five dimeric isoforms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Endogenous angiogenesis inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

VEGF receptor protein-tyrosine kinases: structure and regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

VEGF-Trap: a VEGF blocker with potent antitumor effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Experience with irinotecan for the treatment of malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Safety of anticoagulation use and bevacizumab in patients with glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Novel anti-angiogenic therapies for malignant gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Vascular endothelial growth factor expression in early stage ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

VEGF-targeted therapy: mechanisms of anti-tumour activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Hypertension as a surrogate marker for the activity of anti-VEGF agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Biomarkers of response and resistance to antiangiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

Challenges and pitfalls of combining targeted agents in phase I studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.110

PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization

31 March 2020

1 reference

12 December 2020

Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function

1 reference

12 December 2020

Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

1 reference

12 December 2020

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

1 reference

12 December 2020

Pathology, genetics and cell biology of hemangioblastomas.

1 reference

12 December 2020

Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma

1 reference

12 December 2020

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types

1 reference

12 December 2020

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

1 reference

12 December 2020

Vascular permeability factor gene expression in normal and neoplastic human ovaries

1 reference

12 December 2020

Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo

1 reference

12 December 2020

10.1038/NRCLINONC.2009.110

Identifiers

DOI

1 reference

21 August 2017

1 reference